000 | 02000 a2200517 4500 | ||
---|---|---|---|
005 | 20250517145022.0 | ||
264 | 0 | _c20180619 | |
008 | 201806s 0 0 eng d | ||
022 | _a1557-3265 | ||
024 | 7 |
_a10.1158/1078-0432.CCR-16-3133 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aKato, Shumei | |
245 | 0 | 0 |
_aHyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. _h[electronic resource] |
260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cAug 2017 |
||
300 |
_a4242-4250 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
650 | 0 | 4 |
_aBiomarkers, Tumor _xgenetics |
650 | 0 | 4 |
_aCTLA-4 Antigen _xantagonists & inhibitors |
650 | 0 | 4 | _aCell Cycle Proteins |
650 | 0 | 4 |
_aErbB Receptors _xgenetics |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xdrug effects |
650 | 0 | 4 | _aGenomics |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aImmunotherapy _xadverse effects |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
650 | 0 | 4 |
_aNuclear Proteins _xgenetics |
650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors |
650 | 0 | 4 |
_aProto-Oncogene Proteins _xgenetics |
650 | 0 | 4 |
_aProto-Oncogene Proteins c-mdm2 _xgenetics |
650 | 0 | 4 | _aTreatment Failure |
700 | 1 | _aGoodman, Aaron | |
700 | 1 | _aWalavalkar, Vighnesh | |
700 | 1 | _aBarkauskas, Donald A | |
700 | 1 | _aSharabi, Andrew | |
700 | 1 | _aKurzrock, Razelle | |
773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 23 _gno. 15 _gp. 4242-4250 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1158/1078-0432.CCR-16-3133 _zAvailable from publisher's website |
999 |
_c27024753 _d27024753 |